STOCK PURCHASE AGREEMENTStock Purchase Agreement • April 30th, 2015 • Incyte Corp • Services-commercial physical & biological research • Delaware
Contract Type FiledApril 30th, 2015 Company Industry JurisdictionThis Stock Purchase Agreement (this “Agreement”) is dated as of January 9, 2015, between Agenus Inc., a Delaware corporation (the “Company”), and Incyte Corporation, a Delaware corporation (the “Purchaser”).
LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT BY AND BETWEEN AGENUS INC., 4-ANTIBODY AG, INCYTE EUROPE SARL, AND INCYTE CORPORATION, SOLELY FOR PURPOSES OF SECTION 12.16License, Development and Commercialization Agreement • April 30th, 2015 • Incyte Corp • Services-commercial physical & biological research
Contract Type FiledApril 30th, 2015 Company IndustryTHIS LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (the “Agreement”) is entered into as of January 9, 2015 (the “Execution Date”) by and between Agenus Inc., a Delaware corporation having its principal office at 3 Forbes Road, Lexington, Massachusetts 02421, USA (“Agenus US”) and its wholly-owned subsidiary, 4-Antibody AG, a stock corporation organized under the laws of Switzerland with an office at Hochbergerstrasse 60C, CH-4057, Basel, Switzerland (“4-AB” and, together with Agenus US other than with respect to Section 12.17(s), “Agenus”), and Incyte Europe Sarl, a Swiss limited liability company (a société à responsabilité limitée) having its principal office at Cours de Rive 13, 1204, Geneva, Switzerland (“Incyte”) and solely for purposes of Section 12.16, Incyte Corporation, a Delaware corporation having its principal office at 1801 Augustine Cut-off, Wilmington, Delaware 19803 USA (“Parent”). Agenus and Incyte may be referred to in this Agreement individually as a “Party” a
AMENDMENT TO EMPLOYMENT AGREEMENT April 13, 2015Employment Agreement • April 30th, 2015 • Incyte Corp • Services-commercial physical & biological research
Contract Type FiledApril 30th, 2015 Company IndustryTHIS AMENDMENT to the Employment Agreement (the “Agreement”) by and between INCYTE CORPORATION, a Delaware corporation (the “Company”) and HERVÉ HOPPENOT (the “Executive”), dated as of January 11, 2014.